Related Experiment Video

Updated: Apr 20, 2026

Initial Evaluation of Antibody-conjugates Modified with Viral-derived Peptides for Increasing Cellular Accumulation and Improving Tumor Targeting
11:58

Initial Evaluation of Antibody-conjugates Modified with Viral-derived Peptides for Increasing Cellular Accumulation and Improving Tumor Targeting

Published on: March 8, 2018

8.1K

Preclinical Pharmacokinetic Considerations for the Development of Antibody Drug Conjugates

Amrita V Kamath1, Suhasini Iyer2

  • 1Department of Preclinical and Translational Pharmacokinetics and Pharmacodynamics, Genentech, Inc, 1 DNA Way (Mailstop 463A), South San Francisco, CA, 94080, USA. kamath.amrita@gene.com.

Pharmaceutical Research
|December 3, 2014
PubMed

Insights

Antibody drug conjugates (ADCs) are advanced cancer therapies. Understanding their pharmacokinetics is crucial for optimizing ADC efficacy and toxicity during preclinical development.

Area of Science:

  • Pharmacology
  • Oncology
  • Drug Development

Background:

  • Antibody drug conjugates (ADCs) represent a novel class of targeted cancer therapeutics.
  • ADCs utilize antibodies to deliver cytotoxic payloads specifically to cancer cells.
  • Currently, two ADCs are FDA-approved, with over 30 in clinical trials for various cancers.

Purpose of the Study:

  • To review pharmacokinetic considerations for antibody drug conjugates (ADCs).
  • To discuss tools and strategies for evaluating ADC pharmacokinetics in preclinical stages.
  • To highlight the importance of pharmacokinetics in optimizing ADC design and delivery.

Main Methods:

  • Literature review of pharmacokinetic studies on ADCs.
  • Analysis of factors influencing ADC pharmacokinetics, efficacy, and toxicity.
  • Discussion of preclinical evaluation tools and strategies for ADCs.

Main Results:

  • ADC structure is complex, necessitating a deep understanding of pharmacokinetic attributes.
  • Pharmacokinetics significantly impact ADC efficacy and toxicity, guiding dose and schedule optimization.
  • Preclinical evaluation tools are essential for assessing ADC behavior before clinical trials.

Conclusions:

  • Optimizing ADC design and delivery requires thorough pharmacokinetic evaluation.
  • Understanding ADC pharmacokinetics is critical for successful clinical translation.
  • Preclinical assessment strategies are key to advancing ADC therapeutics.
Keywords:
antibody drug conjugatebiotherapeuticscancerpharmacokineticspreclinical

More Related Videos

Genetic Encoding of a Non-Canonical Amino Acid for the Generation of Antibody-Drug Conjugates Through a Fast Bioorthogonal Reaction11:02

Genetic Encoding of a Non-Canonical Amino Acid for the Generation of Antibody-Drug Conjugates Through a Fast Bioorthogonal Reaction

Published on: September 14, 2018

8.4K
Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody07:36

Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody

Published on: May 16, 2020

6.0K

Related Concept Videos

Phase II Conjugation Reactions: Overview01:14

Phase II Conjugation Reactions: Overview

Conjugation, a key component of phase II biotransformation reactions, is a vital process in drug detoxification. It involves transferring endogenous substances like glucuronic acid, sulfate, and glycine to drugs or their metabolites formed in phase I reactions. These conjugation reactions, often catalyzed by specific enzymes, transform potentially harmful metabolites into inactive, water-soluble forms easily excreted in urine or bile. By enhancing polarity and eliminating pharmacological...
1.3K
Pharmacokinetic–Pharmacodynamic Relationship: Problems01:24

Pharmacokinetic–Pharmacodynamic Relationship: Problems

The empirical approach to drug therapy optimization relies on correlating pharmacological response with administered dosage. Such an approach can be costly, time-consuming, and often yields poor correlation due to variables like formulation factors and drug elimination characteristics. A more precise approach correlates response with plasma drug concentration or the amount of drug in the body, rather than dosage. This is achieved through pharmacokinetic-pharmacodynamic (PK/PD) modeling, which...
105
Drug Distribution: Plasma Protein Binding01:29

Drug Distribution: Plasma Protein Binding

Drugs predominantly attach to plasma proteins, with only a small percentage remaining unbound. The unbound portion can be calculated as one minus the bound fraction. Acidic drugs form large, inactive complexes by reversibly binding to plasma albumin, which prevents them from diffusing across biological barriers. These drug-protein complexes act as reservoirs for the drugs. As the concentration of unbound drugs decreases, these complexes quickly dissociate to release the free drug, maintaining...
13.3K
Dosage Regimens: Partial Pharmacokinetic Parameters01:01

Dosage Regimens: Partial Pharmacokinetic Parameters

It is not uncommon for complete drug pharmacokinetic profiles to remain elusive in pharmacokinetics. This necessitates certain educated assumptions by pharmacokineticists to determine appropriate dosage regimens without comprehensive pharmacokinetic data from animal or human studies. One prevalent assumption is setting the bioavailability factor, denoted as F, to 1 or 100%. This assumption caters to the scenario where a drug doesn't achieve full systemic absorption, resulting in the patient...
356
Biopharmaceutical Factors Influencing Drug Product Design: Overview01:22

Biopharmaceutical Factors Influencing Drug Product Design: Overview

Rational drug product design integrates knowledge of the drug’s physicochemical properties, formulation components, manufacturing techniques, and intended route of administration. Each factor influences the drug’s performance, including how it is released, absorbed, and eliminated in the body.The physicochemical properties of a drug—such as solubility, stability, and particle size—affect its compatibility with excipients and the choice of dosage form. Excipients, though...
514
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
392